These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 28125801)

  • 1. Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray.
    Chen H; Singh RR; Lu X; Huo L; Yao H; Aldape K; Abraham R; Virani S; Mehrotra M; Mishra BM; Bousamra A; Albarracin C; Wu Y; Roy-Chowdhuri S; Kanagal-Shamanna R; Routbort MJ; Medeiros LJ; Patel KP; Broaddus R; Sahin A; Luthra R
    Oncotarget; 2017 Feb; 8(7):10845-10857. PubMed ID: 28125801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
    Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
    Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer.
    Staaf J; Jönsson G; Ringnér M; Baldetorp B; Borg A
    Breast Cancer Res; 2011; 13(6):R129. PubMed ID: 22169037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis.
    Christgen M; van Luttikhuizen JL; Raap M; Braubach P; Schmidt L; Jonigk D; Feuerhake F; Lehmann U; Schlegelberger B; Kreipe HH; Steinemann D
    Oncotarget; 2016 Dec; 7(50):82733-82740. PubMed ID: 27716627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity.
    Gunn S; Yeh IT; Lytvak I; Tirtorahardjo B; Dzidic N; Zadeh S; Kim J; McCaskill C; Lim L; Gorre M; Mohammed M
    BMC Cancer; 2010 Jul; 10():396. PubMed ID: 20667129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target.
    Lee MJ; Kim N; Choung HK; Choe JY; Khwarg SI; Kim JE
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):125-33. PubMed ID: 26141290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.
    Staaf J; Jönsson G; Ringnér M; Vallon-Christersson J; Grabau D; Arason A; Gunnarsson H; Agnarsson BA; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
    Breast Cancer Res; 2010; 12(3):R25. PubMed ID: 20459607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
    Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
    Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.
    Fountzilas G; Dafni U; Bobos M; Kotoula V; Batistatou A; Xanthakis I; Papadimitriou C; Kostopoulos I; Koletsa T; Tsolaki E; Televantou D; Timotheadou E; Koutras A; Klouvas G; Samantas E; Pisanidis N; Karanikiotis C; Sfakianaki I; Pavlidis N; Gogas H; Linardou H; Kalogeras KT; Pectasides D; Dimopoulos MA
    BMC Cancer; 2013 Mar; 13():163. PubMed ID: 23537287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic features of breast cancer reclassified as HER2-amplified by fluorescence in situ hybridization with alternative chromosome 17 probes.
    Blanton KC; Deal AM; Kaiser-Rogers KA; Anders CK; O'Connor SM; Hertel JD; Calhoun BC
    Ann Diagn Pathol; 2020 Oct; 48():151576. PubMed ID: 32805517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
    Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
    Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies.
    Carene D; Tran-Dien A; Lemonnier J; Dalenc F; Levy C; Pierga JY; Jacot W; Canon JL; Richon C; Lacroix L; Caux C; André F; Michiels S
    Breast Cancer Res Treat; 2020 Jan; 179(2):387-401. PubMed ID: 31620934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number.
    Jang MH; Kim EJ; Kim HJ; Chung YR; Park SY
    Breast Cancer Res Treat; 2015 Aug; 153(1):67-77. PubMed ID: 26223814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With
    Hoda RS; Brogi E; Xu J; Ventura K; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
    Arch Pathol Lab Med; 2020 May; 144(5):597-601. PubMed ID: 31647316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].
    Zeng X; Liang ZY; Wu SF; Zhou WX; Gao J; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):584-8. PubMed ID: 17134563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?
    Petroni S; Addati T; Mattioli E; Caponio MA; Quero C; Rubini V; Giotta F; Simone G
    Arch Pathol Lab Med; 2012 Sep; 136(9):993-1000. PubMed ID: 22938586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplification of Chromosome 17 Centromere (CEP17) in Breast Cancer Patients with a Result of HER2 2± by Immunohistochemistry.
    Davies V; Voutsadakis IA
    Cancer Invest; 2020 Feb; 38(2):94-101. PubMed ID: 31977265
    [No Abstract]   [Full Text] [Related]  

  • 18. Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.
    Lamy PJ; Fina F; Bascoul-Mollevi C; Laberenne AC; Martin PM; Ouafik L; Jacot W
    Breast Cancer Res; 2011 Feb; 13(1):R15. PubMed ID: 21288332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer.
    Varga Z; Tubbs RR; Wang Z; Sun Y; Noske A; Kradolfer D; Bosshard G; Jochum W; Moch H; Öhlschlegel C
    Breast Cancer Res Treat; 2012 Apr; 132(3):925-35. PubMed ID: 21698407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 expression in breast cancer with nonamplified HER2 and gains of chromosome 17 centromere.
    Panvichian R; Tantiwetrueangdet A; Wongwaisayawan S; Nampoon A; Lertsithichai P; Leelaudomlipi S
    Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):367-74. PubMed ID: 22417858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.